We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Akubio Announces Appointment of Business Development Director

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Akubio Ltd has announced the appointment of Ian Campbell, formerly business development consultant of The Automation Partnership, as Business Development Director.
 
Ian Campbell, 33, has considerable experience in business development and marketing to the global life sciences industry, as well as a vast knowledge of assay and biomolecular interaction products.  
 
Until recently, Ian was with The Automation Partnership, Hertfordshire, where he was Business Development Consultant, focusing on the integration of technologies to improve the drug discovery process. 

Prior to this, Ian spent three years in business development at Corning Microarray Technology, where his focus was on bringing products to the European pharmaceuticals sector. 

Ian’s previous two years were spent in commercial roles within Biacore AB manufacturers. Ian holds a PhD in Biochemistry and Molecular Biology.
 
Commenting on the appointment, Jerry Walker, Chief Executive Officer of Akubio, said, "We are delighted to appoint Dr Campbell as Business Development Director."

"He has substantial experience and expertise in integrating novel technologies for large biopharmaceutical companies to dramatically improve the drug discovery process."

"Ian also brings with him extensive knowledge in the area of high throughput screening and will be a great asset to Akubio as we continue to grow our business."
 
Ian Campbell said, "Akubio has made tremendous progress in developing its label-free acoustic biosensor products for sensing molecular interactions."

"I look forward to contributing towards the development of this technology for use in drug research and development."